Urological Oncology Predictive Factors for Premature Discontinuation of Docetaxel- Based Systemic Chemotherapy in Men With Castration-Resistant Prostate Cancer

Purpose: The objective was to determine predictive factors for premature discontinua-tion of docetaxel-based systemic chemotherapy in men with castration-resistant pros-tate cancer (CRPC). Materials and Methods: We retrospectively reviewed the medical records of men who were treated with docetaxel-based systemic chemotherapy for CRPC in a single in-stitution between May 2005 and April 2010. After being screened, 30 patients fit the eligibility criteria for inclusion in this study. Group 1 included 12 patients who were treated with five or fewer cycles of docetaxel chemotherapy for CRPC, and group 2 in-cluded 18 patients who were treated with six or more cycles of docetaxel chemotherapy for CRPC. The treatment consisted of 5 mg prednisolone twice daily and 75 mg/m2 doce-taxel once every 3 weeks. Results: The median age was 72 years, and the median Eastern Cooperative Oncology Group (ECOG) performance status was 0. The median baseline prostate-specific anti-gen (PSA) level was 33.8 ng/mL. The median cycle of docetaxel-based chemotherapy was 5.8. Of 30 patients, 13 patients (48.2%) had a decline in PSA of ＞50 % from baseline